ArticleEcancermedicalscience2025
Clinico-radiological outcomes of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders - early results from the SORASTOP study.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The duration of treatment for desmoid-type fibromatosis (DTF) is undefined. This study aimed to evaluate the efficacy of discontinuing sorafenib in responding patients with extremity DTF. We hereby report the initial findings comprising outcomes of 20 evaluable patients enrolled in this study. Methods: This prospective single-arm phase 2 Simon's 2-stage trial enrolled adults with radiologically non-progressive, pain-free (Edmonton Symptom Assessment Scale (ESAS) score <2) extremity DTF post at least 1 year of sorafenib. Sorafenib was discontinued and patients were monitored by clinical examination, magnetic resonance imaging, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Addenbrooke's Cognitive Examination. Disease progression was defined as ≥10% increase in size plus ESAS >5 or ≥20% increase in size. The primary endpoint was a 1-year progression-free survival rate (PFR) after discontinuation. An unplanned analysis of the primary objective among 20 evaluable patients is being presented in this study. Results: 33 patients had a median age of 29.5 years (range: 23-38) and a female-to-male ratio of 1.2:1. Median duration of sorafenib therapy was 24 months (range: 14.5-33.5), and at a median follow-up of 15 months (range: 9-18), 20 patients were evaluable. Among the 20 evaluable patients, 1-year change in tumour size ranged from a 21% decrease to a 32% increase. Three patients restarted sorafenib because of pain with stable disease ( Conclusion: As per the early results, stopping sorafenib can be potentially considered in responding patients with stable extremity DTF after at least 1 year of treatment. With improvement in QoL and an acceptable rate of disease progression upon stopping sorafenib, this treatment discontinuation strategy could be an important consideration in DTF management. Further analysis of the entire study cohort is warranted to establish optimal treatment duration for extremity DTF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.